About Us

Improving Outcomes.
Changing Lives.

We recognise that many of the lives of those who need our products have been touched by tragedy and are changed forever.

At PolyNovo we are driven by improving the outcomes of patients through development and provision of the best surgical solutions possible.

PolyNovo develops innovative medical devices utilising the patented bioabsorbable polymer technology Novosorb®.

NovoSorb is a family of proprietary medical grade polymers that can be expressed in a variety of physical formats. NovoSorb polymers have advantageous properties such as biocompatibility and design flexibility. These properties underpin novel medical devices designed to support tissue repair, before they biodegrade in situ into biocompatible by-products via established pathways.

NovoSorb BTM (Biodegradable Temporising Matrix) is the first product commercialised by PolyNovo. In 2015, following the FDA 510K clearance of BTM, PolyNovo was awarded an $11 million contract and a further $25 million in funding from the US-based Biomedical Advanced Research and Development Authority (BARDA) to complete a trial with BTM for full thickness burns.

We have expanded our manufacturing facility and headquarters in Melbourne, Australia, establishing high quality processes, enabling product innovation and preparing for growth.

NovoSorb BTM Milestones

2015

United States 510K clearance and commercialisation

2016

South African distribution agreement

2018

Distribution partnerships in Saudi Arabia, Israel and India

2018

Australian ARTG listing and commercialisation.

2019

Registered in Singapore and Malaysia

2019

Distribution partnership for Germany, Austria and Switzerland

2019

Awarded European CE mark

2020

European commercialisation.